TheraVet shares rose on the Paris Bourse on Wednesday, following the announcement of the commercial launch in Europe and the UK of the first bone substitute with sustained-release antibiotics.

The veterinary biotechnology company explains that the product, called 'Biocera-Vet Combo-Clean', delivers a high concentration of antibiotics locally, while ensuring the stability of the system thanks to its mechanical strength.

Bone infections are often a major problem in orthopedic surgery, and can occur in up to 5% of operations, explains the Walloon company in a press release.

The bone substitute - which can be mixed with the seven most commonly used antibiotics for bone infections - has a long-lasting action of up to 30 days.

This launch - which reinforces the 'Biocera-Vet' range - was well received on the stock market, with TheraVet shares gaining over 4% in late morning trading. The share is still down 13% since the start of the year.

Copyright (c) 2023 CercleFinance.com. All rights reserved.